Meet The Professors Breast Vol 7, Issue 1

Select Publications

Albain K et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal, node-positive, ER-positive breast cancer (S8814,INT0100). San Antonio Breast Cancer Symposium 2007;Abstract 10.

Albain K et al. Overall survival after cyclophosphamide, Adriamycin, 5-FU, and tamoxifen (CAFT) is superior to T alone in postmenopausal, receptor(+), node(+) breast cancer: New findings from Phase III Southwest Oncology Group Intergroup trial S8814 (INT-0100). Proc ASCO 2001;Abstract 94.

Conlin AK, Seidman AD. Use of the Oncotype DX 21-gene assay to guide adjuvant decision making in early-stage breast cancer. Mol Diagn Ther 2007;11(6):355-60. Abstract

Dowsett M et al. Risk of distant recurrence using Oncotype DX in postmenopausal primary breast cancer patients treated with anastrozole or tamoxifen: A TransATAC study. San Antonio Breast Cancer Symposium 2008;Abstract 53.

Gnant M et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009;360(7):679-91. Abstract

Goldstein LJ et al. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E2197. J Clin Oncol 2008;26(25):4092-9. Abstract

Goldstein L et al. Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol 2008;26(25):4063-71. Abstract

Henry LR et al. The influence of a gene expression profile on breast cancer decisions. J Surg Oncol 2009;[Epub ahead of print]. Abstract

Mamounas E et al. Incorporating the Oncotype DX breast cancer assay into community practice: An expert Q & A and case study sampling. Clin Adv Hematol Oncol 2008;6(2):s1-8. No abstract available